VTE risk factor classification
| ESC2 . | ISTH1 . | ||||
|---|---|---|---|---|---|
| RF category . | Recurrence risk . | Examples . | RF category . | Recurrence risk or risk of index event . | Examples . |
| . | . | . | VTE provoked by a transient risk factor . | ||
| Major transient or reversible RF associated with >10-fold increased risk for the index VTE event (compared with patients without the risk factor) | Low recurrence risk* (<3%/y) | Surgery with GA for >30 min | Major transient RF during the 3 mo before diagnosis of VTE | Half the risk of recurrent VTE (compared with if there was no transient risk factor), when the risk factor occurred up to 3 mo before the VTE or RF was associated with >10-fold increased risk of having a first VTE | Surgery with GA for >30 min |
| Confined to bed in hospital (only bathroom privileges) for ≥3 days because of an acute illness or acute exacerbation of a chronic illness | Confined to bed in hospital (only bathroom privileges) for ≥3 days because of an acute illness | ||||
| Cesarean section | |||||
| Trauma with fractures | |||||
| Transient or reversible factors associated with ≤10-fold increased risk for (index) VTE or | Intermediate recurrence risk (3-8%/y) | Minor surgery (GA for <30 min) | Minor (yet important) transient RF during the 2 mo before diagnosis of VTE | Half the risk of recurrent VTE after stopping anticoagulant therapy (compared with if there was no transient RF), when the RF occurred up to 2 mo before the VTE or RF was associated with a 3- to 10-fold increase in the risk of having a first VTE | Surgery with GA for <30 min |
| Admission to hospital for <3 days with an acute illness | Admission to hospital for <3 days with an acute illness | ||||
| Estrogen therapy/contraception | Estrogen therapy | ||||
| Pregnancy or puerperium | Pregnancy or puerperium | ||||
| Confined to bed out of hospital for ≥3 days with an acute illness | Confined to bed out of hospital for ≥3 days with an acute illness | ||||
| Leg injury (without fracture) associated with reduced mobility for ≥3 days | Leg injury associated with reduced mobility for at least 3 days | ||||
| Long haul flight | |||||
| Nonmalignant persistent risk factors Or | Inflammatory bowel disease | ||||
| Active autoimmune disease | |||||
| No identifiable risk factor | No identifiable risk factor | Unprovoked VTE | |||
| Recurrence risk individualized/stratified using other assessments† | No provoking factors (transient or persistent) | ||||
| VTE provoked by a persistent risk factor | |||||
| High recurrence risk (>8%/y) | Active cancer | Active cancer | Cancer is considered active if any of the following apply: (1) has not received potentially curative treatment; or (2) there is evidence that treatment has not been curative (eg, recurrent or progressive disease); or (3) treatment is ongoing | ||
| At least 1 previous episode of VTE in the absence of a major transient or reversible factor | |||||
| Antiphospholipid antibody syndrome | |||||
| Ongoing nonmalignant condition associated with at least a 2-fold risk of recurrent VTE after stopping anticoagulant therapy | Inflammatory bowel disease. | ||||
| ESC2 . | ISTH1 . | ||||
|---|---|---|---|---|---|
| RF category . | Recurrence risk . | Examples . | RF category . | Recurrence risk or risk of index event . | Examples . |
| . | . | . | VTE provoked by a transient risk factor . | ||
| Major transient or reversible RF associated with >10-fold increased risk for the index VTE event (compared with patients without the risk factor) | Low recurrence risk* (<3%/y) | Surgery with GA for >30 min | Major transient RF during the 3 mo before diagnosis of VTE | Half the risk of recurrent VTE (compared with if there was no transient risk factor), when the risk factor occurred up to 3 mo before the VTE or RF was associated with >10-fold increased risk of having a first VTE | Surgery with GA for >30 min |
| Confined to bed in hospital (only bathroom privileges) for ≥3 days because of an acute illness or acute exacerbation of a chronic illness | Confined to bed in hospital (only bathroom privileges) for ≥3 days because of an acute illness | ||||
| Cesarean section | |||||
| Trauma with fractures | |||||
| Transient or reversible factors associated with ≤10-fold increased risk for (index) VTE or | Intermediate recurrence risk (3-8%/y) | Minor surgery (GA for <30 min) | Minor (yet important) transient RF during the 2 mo before diagnosis of VTE | Half the risk of recurrent VTE after stopping anticoagulant therapy (compared with if there was no transient RF), when the RF occurred up to 2 mo before the VTE or RF was associated with a 3- to 10-fold increase in the risk of having a first VTE | Surgery with GA for <30 min |
| Admission to hospital for <3 days with an acute illness | Admission to hospital for <3 days with an acute illness | ||||
| Estrogen therapy/contraception | Estrogen therapy | ||||
| Pregnancy or puerperium | Pregnancy or puerperium | ||||
| Confined to bed out of hospital for ≥3 days with an acute illness | Confined to bed out of hospital for ≥3 days with an acute illness | ||||
| Leg injury (without fracture) associated with reduced mobility for ≥3 days | Leg injury associated with reduced mobility for at least 3 days | ||||
| Long haul flight | |||||
| Nonmalignant persistent risk factors Or | Inflammatory bowel disease | ||||
| Active autoimmune disease | |||||
| No identifiable risk factor | No identifiable risk factor | Unprovoked VTE | |||
| Recurrence risk individualized/stratified using other assessments† | No provoking factors (transient or persistent) | ||||
| VTE provoked by a persistent risk factor | |||||
| High recurrence risk (>8%/y) | Active cancer | Active cancer | Cancer is considered active if any of the following apply: (1) has not received potentially curative treatment; or (2) there is evidence that treatment has not been curative (eg, recurrent or progressive disease); or (3) treatment is ongoing | ||
| At least 1 previous episode of VTE in the absence of a major transient or reversible factor | |||||
| Antiphospholipid antibody syndrome | |||||
| Ongoing nonmalignant condition associated with at least a 2-fold risk of recurrent VTE after stopping anticoagulant therapy | Inflammatory bowel disease. | ||||